Share-based Payment Arrangement, Expense of Atara Biotherapeutics, Inc. from 31 Dec 2012 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Atara Biotherapeutics, Inc. quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 31 Dec 2012 to 30 Sep 2025.
  • Atara Biotherapeutics, Inc. Share-based Payment Arrangement, Expense for the quarter ending 30 Sep 2025 was $1,225,000, a 81% decline year-over-year.
  • Atara Biotherapeutics, Inc. Share-based Payment Arrangement, Expense for the twelve months ending 30 Sep 2025 was $14,081,000, a 55% decline year-over-year.
  • Atara Biotherapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2024 was $27,001,000, a 41% decline from 2023.
  • Atara Biotherapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $45,386,000, a 16% decline from 2022.
  • Atara Biotherapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $53,838,000, a 0.05% decline from 2021.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

Atara Biotherapeutics, Inc. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $14,081,000 $1,225,000 -$5,197,000 -81% 01 Jul 2025 30 Sep 2025 10-Q 12 Nov 2025 2025 Q3
Q2 2025 $19,278,000 $2,801,000 -$3,535,000 -56% 01 Apr 2025 30 Jun 2025 10-Q 11 Aug 2025 2025 Q2
Q1 2025 $22,813,000 $4,209,000 -$4,188,000 -50% 01 Jan 2025 31 Mar 2025 10-Q 15 May 2025 2025 Q1
Q4 2024 $27,001,000 $5,846,000 -$4,081,000 -41% 01 Oct 2024 31 Dec 2024 10-K 07 Mar 2025 2024 FY
Q3 2024 $31,082,000 $6,422,000 -$4,721,000 -42% 01 Jul 2024 30 Sep 2024 10-Q 12 Nov 2025 2025 Q3
Q2 2024 $35,803,000 $6,336,000 -$6,216,000 -50% 01 Apr 2024 30 Jun 2024 10-Q 11 Aug 2025 2025 Q2
Q1 2024 $42,019,000 $8,397,000 -$3,367,000 -29% 01 Jan 2024 31 Mar 2024 10-Q 15 May 2025 2025 Q1
Q4 2023 $45,386,000 $9,927,000 -$1,436,000 -13% 01 Oct 2023 31 Dec 2023 10-K 07 Mar 2025 2024 FY
Q3 2023 $46,822,000 $11,143,000 -$2,880,000 -21% 01 Jul 2023 30 Sep 2023 10-Q 12 Nov 2024 2024 Q3
Q2 2023 $49,702,000 $12,552,000 -$1,565,000 -11% 01 Apr 2023 30 Jun 2023 10-Q 12 Aug 2024 2024 Q2
Q1 2023 $51,267,000 $11,764,000 -$2,571,000 -18% 01 Jan 2023 31 Mar 2023 10-Q 09 May 2024 2024 Q1
Q4 2022 $53,838,000 $11,363,000 -$2,665,000 -19% 01 Oct 2022 31 Dec 2022 10-K 28 Mar 2024 2023 FY
Q3 2022 $56,503,000 $14,023,000 +$261,000 +1.9% 01 Jul 2022 30 Sep 2022 10-Q 01 Nov 2023 2023 Q3
Q2 2022 $56,242,000 $14,117,000 +$310,000 +2.2% 01 Apr 2022 30 Jun 2022 10-Q 08 Aug 2023 2023 Q2
Q1 2022 $55,932,000 $14,335,000 +$2,067,000 +17% 01 Jan 2022 31 Mar 2022 10-Q 08 May 2023 2023 Q1
Q4 2021 $53,865,000 $14,028,000 +$2,524,000 +22% 01 Oct 2021 31 Dec 2021 10-K 08 Feb 2023 2022 FY
Q3 2021 $51,341,000 $13,762,000 +$507,000 +3.8% 01 Jul 2021 30 Sep 2021 10-Q 08 Nov 2022 2022 Q3
Q2 2021 $50,834,000 $13,807,000 -$141,000 -1% 01 Apr 2021 30 Jun 2021 10-Q 08 Aug 2022 2022 Q2
Q1 2021 $50,975,000 $12,268,000 -$376,000 -3% 01 Jan 2021 31 Mar 2021 10-Q 05 May 2022 2022 Q1
Q4 2020 $51,351,000 $11,504,000 -$570,000 -4.7% 01 Oct 2020 31 Dec 2020 10-K 08 Feb 2023 2022 FY
Q3 2020 $51,921,000 $13,255,000 +$1,103,000 +9.1% 01 Jul 2020 30 Sep 2020 10-Q 04 Nov 2021 2021 Q3
Q2 2020 $50,818,000 $13,948,000 -$1,253,000 -8.2% 01 Apr 2020 30 Jun 2020 10-Q 09 Aug 2021 2021 Q2
Q1 2020 $52,071,000 $12,644,000 +$375,000 +3.1% 01 Jan 2020 31 Mar 2020 10-Q 04 May 2021 2021 Q1
Q4 2019 $51,696,000 $12,074,000 +$2,521,000 +26% 01 Oct 2019 31 Dec 2019 10-K 28 Feb 2022 2021 FY
Q3 2019 $49,175,000 $12,152,000 +$2,900,000 +31% 01 Jul 2019 30 Sep 2019 10-Q 09 Nov 2020 2020 Q3
Q2 2019 $46,275,000 $15,201,000 +$7,203,000 +90% 01 Apr 2019 30 Jun 2019 10-Q 05 Aug 2020 2020 Q2
Q1 2019 $39,072,000 $12,269,000 +$5,255,000 +75% 01 Jan 2019 31 Mar 2019 10-Q 06 May 2020 2020 Q1
Q4 2018 $33,817,000 $9,553,000 +$3,456,000 +57% 01 Oct 2018 31 Dec 2018 10-K 01 Mar 2021 2020 FY
Q3 2018 $30,361,000 $9,252,000 +$3,252,000 +54% 01 Jul 2018 30 Sep 2018 10-Q 07 Nov 2019 2019 Q3
Q2 2018 $27,109,000 $7,998,000 +$2,342,000 +41% 01 Apr 2018 30 Jun 2018 10-Q 08 Aug 2019 2019 Q2
Q1 2018 $24,767,000 $7,014,000 +$1,667,000 +31% 01 Jan 2018 31 Mar 2018 10-Q 09 May 2019 2019 Q1
Q4 2017 $23,100,000 $6,097,000 +$4,441,000 +268% 01 Oct 2017 31 Dec 2017 10-K 27 Feb 2020 2019 FY
Q3 2017 $18,659,000 $6,000,000 +$731,000 +14% 01 Jul 2017 30 Sep 2017 10-Q 06 Nov 2018 2018 Q3
Q2 2017 $17,928,000 $5,656,000 +$521,000 +10% 01 Apr 2017 30 Jun 2017 10-Q 01 Aug 2018 2018 Q2
Q1 2017 $17,407,000 $5,347,000 +$623,000 +13% 01 Jan 2017 31 Mar 2017 10-Q 08 May 2018 2018 Q1
Q4 2016 $16,784,000 $1,656,000 -$1,309,000 -44% 01 Oct 2016 31 Dec 2016 10-K 26 Feb 2019 2018 FY
Q3 2016 $18,093,000 $5,269,000 +$3,035,000 +136% 01 Jul 2016 30 Sep 2016 10-Q 09 Nov 2017 2017 Q3
Q2 2016 $15,058,000 $5,135,000 +$2,566,000 +100% 01 Apr 2016 30 Jun 2016 10-Q 07 Aug 2017 2017 Q2
Q1 2016 $12,492,000 $4,724,000 +$2,241,000 +90% 01 Jan 2016 31 Mar 2016 10-Q 04 May 2017 2017 Q1
Q4 2015 $10,251,000 $2,965,000 -$2,809,000 -49% 01 Oct 2015 31 Dec 2015 10-K 27 Feb 2018 2017 FY
Q3 2015 $13,060,000 $2,234,000 +$1,748,000 +360% 01 Jul 2015 30 Sep 2015 10-Q 04 Nov 2016 2016 Q3
Q2 2015 $11,312,000 $2,569,000 +$2,045,000 +390% 01 Apr 2015 30 Jun 2015 10-Q 08 Aug 2016 2016 Q2
Q1 2015 $9,267,000 $2,483,000 -$834,000 -25% 01 Jan 2015 31 Mar 2015 10-Q 06 May 2016 2016 Q1
Q4 2014 $10,101,000 $5,774,000 01 Oct 2014 31 Dec 2014 10-K 09 Mar 2017 2016 FY
Q3 2014 $486,000 +$147,000 +43% 01 Jul 2014 30 Sep 2014 10-Q 06 Nov 2015 2015 Q3
Q2 2014 $524,000 01 Apr 2014 30 Jun 2014 10-Q 07 Aug 2015 2015 Q2
Q1 2014 $3,317,000 01 Jan 2014 31 Mar 2014 10-Q 11 May 2015 2015 Q1
Q3 2013 $339,000 01 Jul 2013 30 Sep 2013 10-Q 12 Nov 2014 2014 Q3
Q4 2012 $292,000 22 Aug 2012 31 Dec 2012 10-K 26 Feb 2015 2014 FY

Atara Biotherapeutics, Inc. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $27,001,000 -$18,385,000 -41% 01 Jan 2024 31 Dec 2024 10-K 07 Mar 2025 2024 FY
2023 $45,386,000 -$8,452,000 -16% 01 Jan 2023 31 Dec 2023 10-K 07 Mar 2025 2024 FY
2022 $53,838,000 -$27,000 -0.05% 01 Jan 2022 31 Dec 2022 10-K 28 Mar 2024 2023 FY
2021 $53,865,000 +$2,514,000 +4.9% 01 Jan 2021 31 Dec 2021 10-K 08 Feb 2023 2022 FY
2020 $51,351,000 -$345,000 -0.67% 01 Jan 2020 31 Dec 2020 10-K 08 Feb 2023 2022 FY
2019 $51,696,000 +$17,879,000 +53% 01 Jan 2019 31 Dec 2019 10-K 28 Feb 2022 2021 FY
2018 $33,817,000 +$10,717,000 +46% 01 Jan 2018 31 Dec 2018 10-K 01 Mar 2021 2020 FY
2017 $23,100,000 +$6,316,000 +38% 01 Jan 2017 31 Dec 2017 10-K 27 Feb 2020 2019 FY
2016 $16,784,000 +$6,533,000 +64% 01 Jan 2016 31 Dec 2016 10-K 26 Feb 2019 2018 FY
2015 $10,251,000 +$150,000 +1.5% 01 Jan 2015 31 Dec 2015 10-K 27 Feb 2018 2017 FY
2014 $10,101,000 +$8,388,000 +490% 01 Jan 2014 31 Dec 2014 10-K 09 Mar 2017 2016 FY
2013 $1,713,000 +$1,421,000 +487% 01 Jan 2013 31 Dec 2013 10-K 04 Mar 2016 2015 FY
2012 $292,000 01 Jan 2012 31 Dec 2012 10-K 26 Feb 2015 2014 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.